Analyst Reco. Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 21/04/2026 BST			5-day change	1st Jan Change
1,732.00 ^DKK	-2.42%		-6.02%	-14.55%

05:57am	Nordic Equities in North America - Astra Zeneca slips 1.1 percent	FW
04-15	Nordic Equities in North America - Astra Zeneca Gains 0.9 Percent	FW

Analyst Reco.

04-14	Jyske Bank upgrades Genmab to Buy from Hold, sets price target at DKK 2,300 - BN	FW
03-23	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT
03-06	UBS Lowers Price Target for Genmab to 2,600 Danish Kroner (from 2,750), Reiterates Buy	FW
03-04	SHB Sees Multiple Potential Share Price Triggers for Genmab, Raises Target Price	FW
03-03	Handelsbanken Raises Genmab Price Target to 2,220 Danish Kroner (from 2,200), Reiterates Buy - BN	FW
02-23	Bernstein Raises Price Target for Genmab to 1,400 Danish Kroner (from 1,015), Reiterates Underperform - BN	FW
02-19	BofA Bullish on Genmab's FY26 Catalyst Path; Buy Rating Maintained	MT
02-18	Genmab: 2025 miss and cautious 2026 targets erode investor confidence
02-18	DNB Carnegie Raises Target Price for Genmab to 2,300 Danish Kroner (from 2,235), Reiterates Buy Recommendation	FW
02-18	Goldman Sachs Lowers Price Target for Genmab to 1,771 Danish Kroner (from 1,793), Reiterates Neutral Rating - BN	FW
02-17	Jefferies Resumes Coverage of Genmab with Buy Rating, Citing Attractive Valuation Case	FW
02-17	Jefferies Resumes Coverage of Genmab with Buy Rating and Price Target of 2,650 Danish Kroner	FW
02-04	Goldman Sachs Lowers Price Target for Genmab to 1,793 Danish Kroner (from 1,880), Reiterates Neutral - BN	FW
01-21	DNB Carnegie Upgrades Genmab to Buy, Raises PT	MT
01-21	DNB Carnegie Upgrades Genmab to Buy (Hold), Raises Target Price to 2,235 Danish Kroner (from 1,985)	FW
01-20	BofA Lifts Genmab Price Target, Estimates on Expected 'Catalyst Rich' FY26	MT
01-19	SHB: Overreaction in the Market to Genmab's Epkinly Study	FW
01-15	Jyske Bank Raises Genmab Target Price to 2,300 Danish Kroner (2,000), Reiterates Hold - BN	FW
01-08	UBS Raises Price Target for Genmab to 2,750 Danish Kroner (from 2,700), Reiterates Buy	FW
12-30	Genmab Faces 'Transformative' Year Ahead With Pivotal Trial Readouts, Truist Securities Says	MT
12-30	Genmab Kept at Buy as Truist Securities Forecasts 'Transformative' Year Ahead	MT
12-30	DNB Carnegie Trims Genmab PT, Maintains Hold Rating	MT
12-30	SHB: Genmab's Decision to Halt Acasunlimab Development Deemed Logical	FW
12-30	DNB Carnegie Lowers Price Target for Genmab to 1,985 Danish Kroner (from 2,050), Reiterates Hold	FW
12-19	Deutsche Bank Raises Target Price for Genmab to 2,400 Danish Kroner (2,000), Reiterates Buy	FW